Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934146 | 0.93 | MME (0.40) | TRPA1CYP1A2MMEACECPA1 | |
| SCHEMBL4933384 | 0.90 | THRB (0.44) | TRPA1CYP1A2MMEACECPA1 | |
| SCHEMBL4931288 | 0.89 | MRGPRX4 (0.39) | MMEACECPA1ACE2MRGPRX4 | |
| SCHEMBL4931731 | 0.89 | MRGPRX4 (0.40) | MMEACECPA1ACE2MRGPRX4 | |
| SCHEMBL4933984 | 0.88 | FFAR1 (0.39) | MRGPRX4FFAR4FFAR1 | |
| SCHEMBL5111939 | 0.87 | ALDH1A1 (0.42) | MMEACECPA1ACE2MRGPRX4 | |
| SCHEMBL4931145 | 0.87 | MME (0.40) | TRPA1MMEACECPA1ACE2 | |
| SCHEMBL5110521 | 0.87 | MRGPRX4 (0.39) | MMEACECPA1ACE2MRGPRX4 | |
| SCHEMBL4932666 | 0.87 | FFAR1 (0.38) | TRPA1MRGPRX4FFAR1 | |
| SCHEMBL4934220 | 0.86 | MME (0.42) | MMEACECPA1ACE2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | TRPA1 675/4885CYP1A2 1307/4885MME 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.